GlassScriptPhysician profile
Erin C Angelo
NPI 1558112862
$569.06
in general payments reported to CMS, 2019-2025
11 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $102 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $131.97 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organogenesis INC. | $125.13 | 2025 | Apligraf, Puraply Wound Matrix, Affinity |
| Regeneron Healthcare Solutions, INC. | $56.79 | 2025 | Libtayo, Dupixent |
| Revance Therapeutics, INC. | $53.83 | 2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $43.96 | 2024-2025 | |
| Bard Peripheral Vascular, INC. | $35.02 | 2025 | Venclose Maven Catheter |
| Boston Scientific Corporation | $34.19 | 2024 | Varithena Administration Pack |
| Janssen Biotech, INC. | $26.98 | 2025 | Tremfya |
| Amgen INC. | $25.00 | 2024 | Otezla |
| Incyte Corporation | $20.50 | 2024 | Opzelura |
| Biofrontera INC. | $15.69 | 2025 | Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Angelo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.